1.35
前日終値:
$1.47
開ける:
$1.43
24時間の取引高:
1.60M
Relative Volume:
0.75
時価総額:
$92.47M
収益:
$5.03M
当期純損益:
$-185.41M
株価収益率:
-0.4369
EPS:
-3.09
ネットキャッシュフロー:
$-139.79M
1週間 パフォーマンス:
-15.09%
1か月 パフォーマンス:
-60.76%
6か月 パフォーマンス:
-87.96%
1年 パフォーマンス:
-90.94%
Pliant Therapeutics Inc Stock (PLRX) Company Profile
名前
Pliant Therapeutics Inc
セクター
電話
650-481-6770
住所
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
PLRX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
PLRX
Pliant Therapeutics Inc
|
1.35 | 92.47M | 5.03M | -185.41M | -139.79M | -3.09 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-03-04 | 再開されました | Cantor Fitzgerald | Neutral |
2025-03-04 | ダウングレード | Needham | Buy → Hold |
2025-03-03 | ダウングレード | Leerink Partners | Outperform → Market Perform |
2025-03-03 | ダウングレード | Stifel | Buy → Hold |
2025-02-10 | ダウングレード | Canaccord Genuity | Buy → Hold |
2025-02-10 | ダウングレード | Citigroup | Buy → Neutral |
2025-02-10 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2025-02-10 | ダウングレード | JP Morgan | Overweight → Neutral |
2025-02-10 | ダウングレード | Oppenheimer | Outperform → Perform |
2025-02-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2025-02-10 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
2024-09-09 | 再開されました | Leerink Partners | Outperform |
2023-12-08 | 開始されました | Wells Fargo | Overweight |
2023-05-18 | 開始されました | Canaccord Genuity | Buy |
2023-04-13 | 開始されました | Robert W. Baird | Outperform |
2022-12-14 | 開始されました | Stifel | Buy |
2022-12-07 | 開始されました | JP Morgan | Overweight |
2022-09-01 | 開始されました | Citigroup | Buy |
2022-07-20 | 開始されました | SVB Leerink | Outperform |
2022-05-25 | 開始されました | Cantor Fitzgerald | Overweight |
2021-12-10 | 開始されました | Oppenheimer | Outperform |
2021-11-24 | 開始されました | RBC Capital Mkts | Outperform |
2021-11-03 | 開始されました | H.C. Wainwright | Buy |
2021-04-20 | 開始されました | BTIG Research | Buy |
2021-04-05 | 開始されました | Citigroup | Buy |
2020-06-29 | 開始されました | Citigroup | Buy |
2020-06-29 | 開始されました | Cowen | Outperform |
2020-06-29 | 開始されました | Needham | Buy |
2020-06-29 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Pliant Therapeutics Inc (PLRX) 最新ニュース
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - PR Newswire
PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know - TradingView
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Pliant Therapeutics – PLRX - MENAFN.COM
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant ... - Bluefield Daily Telegraph
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - GlobeNewswire Inc.
TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Pliant Therapeutics Inc - GuruFocus
Pliant discontinues Phase 2b/3 trial of IPF treatment bexotegrast - Pulmonary Fibrosis News
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus.com
Pliant Therapeutics (NASDAQ:PLRX) Receives “Neutral” Rating from HC Wainwright - Defense World
Pliant Therapeutics Announces Interim Phase 1 Data for - GlobeNewswire
Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types - Benzinga
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - Markets Insider
Pliant Therapeutics Says Experimental Cancer Drug Shows Antitumor Activity in Phase 1 Trial - Marketscreener.com
Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’ - Yahoo Finance
Pliant Therapeutics adopts shareholder rights plan By Investing.com - Investing.com Australia
Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor - The Business Journals
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - The Malaysian Reserve
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus.com
Pliant Therapeutics Signs Shareholder Rights Agreement -March 13, 2025 at 08:32 am EDT - Marketscreener.com
Pliant Therapeutics adopts shareholder rights plan - Investing.com India
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement - The Manila Times
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement to Protect Shareholder Interests - Nasdaq
Pliant Therapeutics Shields Against Hostile Takeover with Strategic Rights Plan - StockTitan
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Pliant Therapeutics - MENAFN.COM
Pliant dives 49% as it abandons phase 2 trial of bexotegrast for IPF - MSN
Pliant Therapeutics (NASDAQ:PLRX) Cut to “Hold” at Leerink Partnrs - Defense World
Leerink Partners Downgrades Pliant Therapeutics (MUN:9PT) - Nasdaq
If You Don’t Bullish On Pliant Therapeutics Inc (NASDAQ: PLRX) Now, You’ll Regret Your Decision Later - Stocks Register
Pliant halts lung fibrosis trial amid safety concerns - The Pharma Letter
Pliant Therapeutics (NASDAQ:PLRX) Price Target Cut to $3.00 by Analysts at Royal Bank of Canada - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc- PLRX - PR Newswire
Leerink Partners Downgrades Pliant Therapeutics (PLRX) - MSN
Pliant Therapeutics stock tumbles amid IPF trial cancellation - MSN
Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future - Benzinga
Hold Rating on Pliant Therapeutics Amid Trial Discontinuation and Safety Concerns - TipRanks
Pliant downgraded at Stifel on bexotegrast trial discontinuation - MSN
Pliant stock downgraded at Stifel trial discontinuation (PLRX:NASDAQ) - Seeking Alpha
This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Stifel Downgrades Pliant Therapeutics to Hold From Buy, Adjusts Price Target to $3 From $32 - Marketscreener.com
Needham Downgrades Pliant Therapeutics to Hold From Buy -March 04, 2025 at 08:28 am EST - Marketscreener.com
Pliant Therapeutics: Hold Rating Maintained Amid Trial Discontinuation and Adjusted Financial Outlook - TipRanks
RBC Cuts Price Target on Pliant Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk - Marketscreener.com
Pliant Therapeutics Reports Q4 2024 Results and Updates - MSN
Pliant Therapeutics price target lowered to $1.50 from $4 at Citi - TipRanks
Citi cuts Pliant Therapeutics stock target to $1.50, maintains neutral By Investing.com - Investing.com Canada
Cautious Hold Rating on Pliant Therapeutics Amid Uncertainty Over Bexotegrast Trial and Financial Outlook - TipRanks
Citi cuts Pliant Therapeutics stock target to $1.50, maintains neutral - Investing.com India
Hold Rating on Pliant Therapeutics Amidst BEACON-IPF Study Discontinuation and Uncertainty in Pipeline Prioritization - TipRanks
Pliant Therapeutics Inc (PLRX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):